Five things for pharma marketers to know: Monday, June 20, 2016

1. Novartis plans to launch five biosimilars by 2020. Richard Francis, the head of the Swiss drugmaker's generic arm, said in an interview that biosimilar versions of AbbVie's Humira, Amgen's Enbrel and Neulasta, Johnson & Johnson's Remicade, and Roche's Rituxan would arrive in pharmacies over the next four years. (Reuters)

2. The winners of the Cannes Lions Health festival have been announced. Visit our series page, Live at Cannes, to see all the winners and analysis from the weekend.

3. The directors of the Making A Murderer documentary are planning to film an adaptation of “America's Most Admired Lawbreaker,” The Huffington Post's investigation into Johnson & Johnson's marketing of antipsychotic Risperdal. (The Huffington Post)

4. Biogen plans to stop manufacturing drugs in its Cambridge, Massachusetts, facility by the end of the year. The drugmaker is looking to sell or close the manufacturing plant at its headquarters, a move that would affect as many as 285 employees. (The Boston Globe)

5. The National for Health and Care Excellence affirmed a previous ruling against Vertex cystic fibrosis treatment Orkambi, saying the drug's benefit is not worth its “considerable cost.” (PharmaTimes)